

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claims 1-4 (Cancelled)

5(Currently Amended): A method for detecting, or screening a subject for, endocrine cancer comprising:

- (a) ~~obtaining a biological sample from a subject;~~
- (b) ~~—~~detecting the amount of kallikrein 13 in a biological sample from a subject; and
- (e) (b) comparing said amount of kallikrein 13 detected to a predetermined standard,

wherein detection of a level of kallikrein 13 in said sample that is significantly different than that of a standard is ~~indicative~~ diagnostic of endocrine cancer.

Claims 6-29 (Cancelled)

30(New): The method of claim 5, wherein said level of kallikrein 13 in said sample is increased in comparison with said standard.

31(New): The method of claim 5, wherein said detecting step comprises detecting the kallikrein 13 using antibodies specifically reactive with kallikrein 13 or a part thereof.

32(New): The method of claim 5, wherein said detecting step comprises incubating said biological sample from the subject with a first antibody specific for kallikrein 13 which is directly or indirectly labeled with a detectable substance, and a second antibody

specific for kallikrein 13 which is immobilized; and detecting the detectable substance thereby quantitating kallikrein 13 in the biological sample.

33(New): The method of claim 5, which further comprises detecting one or more of a biomarker selected from the group consisting of human stratum corneum chymotryptic enzyme (HSCCE), haptoglobin alpha, osteopontin, kallikrein 2, kallikrein 3, kallikrein 4, kallikrein 5, kallikrein 6, kallikrein 8, kallikrein 10, kallikrein 11, kallikrein 14, kallikrein 15, CA125, CA15-3, CA19-9, OVX1, lysophosphatidic acid (LPA) and carcinoembryonic antigen (CEA).

34(New): The method of claim 33, wherein said biomarker is selected from the group consisting of kallikrein 5 and kallikrein 11.

35(New): The method of claim 5, wherein said endocrine cancer is ovarian cancer.

36(New): The method of claim 35, wherein the standard comprises normal levels of kallikrein 13 in samples of the same type obtained from control subjects not afflicted with ovarian cancer or who have kallikrein negative tumors.

37(New): The method of claim 36, wherein the levels of kallikrein 13 in the sample from the subject are increased compared to the standard and are diagnostic of a condition selected from the group consisting of early stage ovarian cancer, no residual tumors, optimal debulking success, tumors characterized by clear cell and mucinous histotypes, and longer survival.

38(New): The method of claim 37 wherein the ovarian cancer comprises non-serous epithelial tumors.

39(New): The method of claim 35, further comprising:

(a) contacting an amount of an antibody which binds to kallikrein 13, with said sample from the subject so as to form a complex comprising the antibody and kallikrein 13 in the sample;

(b) determining or detecting the presence or amount of complex formation in the sample; and

(c) comparing the amount of kallikrein 13 present in the sample with the amount of kallikrein 13 in a control,

wherein a higher amount of kallikrein 13 in the sample compared with the amount in the control is indicative of a prognosis of a subject with ovarian cancer selected from the group consisting of a favorable prognosis, early stage disease, no residual tumor, optimal debulking success, longer progression-free survival (PFS) and overall survival (OS).

40(New): The method of claim 39, wherein the control comprises normal levels of kallikrein 13 in samples of the same type obtained from control subjects not afflicted with ovarian cancer or who have kallikrein negative tumors.

41(New): The method of claim 40, wherein the subject has a non-serous epithelial tumor.